Production & Sales

Teva Pharmaceuticals USA recalls Losartan Potassium 25mg and 100mg Tablets USP sold exclusively to Golden State Medical Supply

Teva Pharmaceuticals USA has initiated a voluntary recall in the US, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength).

Kite announces plans for new state-of-the-art facility to expand cell therapy production capabilities

Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer.

GSK invests $100m to boost vaccine manufacturing at US facility

British drugmaker GlaxoSmithKline (GSK) is set to invest $100m to expand long-term vaccine manufacturing capabilities at its Hamilton facility in Montana, US.

Lilly announces sale of legacy antibiotics brands and manufacturing facility in China

Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China that produces Ceclor, to Eddingpharm, a China-based specialty pharmaceutical company.

Teva launches generic version of VESIcare (solifenacin succinate) tablets in US

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.

MS Pharma to acquire European pharmaceutical firm Genepharm

Jordan-based MS Pharma has agreed to acquire European pharmaceutical firm, Genepharm, for an undisclosed sum.

Sun Pharma launches ready-to-infuse INFUGEM in the US

Sun Pharmaceutical Industries Ltd. announced that INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the U.S.

Merck invests in expansion of manufacturing capacity for biotech medicines

Merck, a leading science and technology company, has announced an investment of €150m in its manufacturing site at Aubonne, Switzerland, to expand manufacturing capacity for its biotech medicines.

bluebird bio opens gene and cell therapy manufacturing facility in North Carolina

bluebird bio announced the official opening of its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease.